OSLO, Norway , 13 June, 2017 /PRNewswire/ --
Nordic Nanovector ASA (OSE: NANO) will host a conference call on Wednesday, 14 June at 1 pm
CET to present updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® in patients with
relapsed/refractory indolent non-Hodgkin's lymphoma. These data will be presented at the International Conference on Malignant
Lymphoma (ICML) on 14-17 June in Lugano, Switzerland.
Conference call details:
The call is scheduled for Wednesday, 14 June 2017 at 1 pm
CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and
confirmation code below:
|
Location
|
Phone
Number
|
|
Norway
|
+47-2100-2610
|
|
Switzerland
|
+41 (0)44-580-7206
|
|
Sweden
|
+46 (0)8-5033-6574
|
|
United Kingdom
|
+44 (0)330-336-9105
|
|
United States and International
|
+1 719-457-1036
|
Conference ID: 5732602
The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Presentation/2017 from
1 pm CET on 14 June 2017.
For further information, please contact:
IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47-91-51-95-76
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-282-2948/+44-207-282-2949
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical
needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological
cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates
(ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical
need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of
major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic
Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core
markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/invitation-to-conference-call-for-updated-clinical-trial-results-reported-at-the-international-confe,c2286849